By Daniella Parra
Araris Biotech AG, a Swiss oncology biotech firm, has partnered with Chugai Pharmaceutical to develop advanced antibody-drug conjugates (ADCs) using Araris’ AraLinQ platform, the company said.
The collaboration aims to create ADCs in cancer treatments by incorporating multiple drug warheads without requiring antibody engineering, they said.
The company said Chugai will pay an upfront fee, fund research, and oversee development, manufacturing, and commercialization if it exercises its licensing option.
“We are excited to enter a collaboration with Chugai Pharmaceutical and look forward to working closely with the Chugai team and apply our ADC technology to develop next-generation ADCs with improved efficacy and tolerability,” said Dr. Dragan Grabulovski, CEO and co-founder of Araris.
Contact:
